PDCD1 and renal cell carcinoma: Our previous study showed that increased eosinophil proportion of ≥3.0% is an effective biomarker for predicting irAE occurrences in patients with renal cell carcinoma who received anti‐CTLA‐4 plus anti‐PD‐1 combination therapy.21